13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2018-12-31, filed 2019-02-13, with 22 holding rows worth $113,865,000.
- Accession
- 0001567619-19-003836
- Filer
- CIK 1440771
- Filed
- 2019-02-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2018
A holdings report, 22 entries on the cover page, a total value of $113,865,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $113,865,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| AMARIN CORP PLC | 023111206 | SPONS ADR NEW | 1,100,000 | $14,971,000 | thousands by filing date | |
| BIODELIVERY SCIENCES INTL IN | 09060J106 | COM | 3,981,867 | $14,733,000 | thousands by filing date | |
| BIOSPECIFICS TECHNOLOGIES | 090931106 | COM | 217,395 | $13,174,000 | thousands by filing date | |
| CUMBERLAND PHARMACEUTICALS I | 230770109 | COM | 1,313,429 | $7,920,000 | thousands by filing date | |
| APOLLO ENDOSURGERY INC | 03767D108 | COM | 2,185,426 | $7,540,000 | thousands by filing date | |
| NEOS THERAPEUTICS INC | 64052L106 | COM | 4,210,153 | $6,947,000 | thousands by filing date | |
| HTG MOLECULAR DIAGNOSTICS IN | 40434H104 | COM | 2,675,889 | $6,797,000 | thousands by filing date | |
| VANDA PHARMACEUTICALS INC | 921659108 | COM | 220,848 | $5,771,000 | thousands by filing date | |
| OPIANT PHARMACEUTICALS INC | 683750103 | COM | 357,960 | $5,173,000 | thousands by filing date | |
| OPHTHOTECH CORP | 683745103 | COM | 4,072,301 | $4,887,000 | thousands by filing date | |
| ALIMERA SCIENCES INC | 016259103 | COM | 6,547,774 | $4,702,000 | thousands by filing date | |
| FOAMIX PHARMACEUTICALS LTD | M46135105 | SHS | 1,293,177 | $4,643,000 | thousands by filing date | |
| CTI BIOPHARMA CORP | 12648L601 | COM | 5,726,579 | $4,201,000 | thousands by filing date | |
| VIVEVE MED INC | 92852W204 | COM NEW | 3,418,402 | $3,589,000 | thousands by filing date | |
| OXFORD IMMUNOTEC GLOBAL PLC | G6855A103 | ORD SHS | 222,321 | $2,841,000 | thousands by filing date | |
| AFFIMED N V | N01045108 | COM | 714,079 | $2,221,000 | thousands by filing date | |
| CORREVIO PHARMA CORP | 22026V105 | COM | 424,101 | $1,056,000 | thousands by filing date | |
| CHEMBIO DIAGNOSTICS | 163572209 | COM | 147,011 | $832,000 | thousands by filing date | |
| ALPHATEC HLDGS INC | 02081G201 | COM NEW | 338,278 | $775,000 | thousands by filing date | |
| MOLECULAR TEMPLATES INC | 608550109 | COM | 114,710 | $463,000 | thousands by filing date | |
| NOVELION THERAPEUTICS INC | 67001K202 | COM NEW | 531,662 | $447,000 | thousands by filing date | |
| CATABASIS PHARMACEUTICALS IN | 14875P206 | COM NEW | 41,688 | $182,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001567619-19-003836 | this filing | 2019-02-13 | acceptance time not in the bulk data set |